Financial Data and Key Metrics Changes - Revenue for Q1 2025 increased by 47% year-over-year to $7,900,000, exceeding guidance of $7,800,000, driven by balanced growth in the Vinia business [6][22] - Gross profit rose by 53% to $4,600,000, representing a gross margin of 58.5%, up from 56.2% in the same quarter last year [22][23] - Net losses for Q1 2025 totaled $2,300,000, or $0.13 per share, compared to a net loss of $6,600,000, or $0.48 per share in the same quarter last year [23][24] Business Line Data and Key Metrics Changes - The Direct to Consumer Health and Wellness Products Division, led by Vinia, accounted for the majority of revenue, with total active subscribers exceeding 50,000 in the USA [6][10] - The Amazon channel represented 20% of the business, showing improvements in customer conversion and repeat purchase rates [6] - The CDMO services division has signed multiple customers, including a partnership with Tate and Lyle for developing next-generation plant-based sweeteners [16][17] Market Data and Key Metrics Changes - The company reported a significant increase in gross margins, attributed to scaling operations and cost efficiencies [7][8] - The rollout of new products, including superfood tea and coffee, is expected to capture additional market segments [10][12] Company Strategy and Development Direction - The company aims to achieve adjusted EBITDA breakeven at $11,000,000 to $12,000,000 in quarterly revenue by the second half of 2025 [18] - Strategic focus includes expanding the direct-to-consumer portfolio, investing in R&D for process improvements, and building AI-powered tools for CDMO services [19] - The company plans to launch new products targeting younger consumers and expand into the hydration and beauty markets [62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to execute and deliver on the company's mission to democratize life-changing compounds [25] - The company is optimistic about the growth potential in the pharmaceutical sector, driven by increasing interest in non-GMO and plant-based compounds [72][74] - Management highlighted the importance of regulatory flexibility and the potential for significant revenue opportunities in the pharmaceutical market [73] Other Important Information - Cash and cash equivalents as of March 31, 2025, totaled $3,400,000, an increase from $2,400,000 at the end of 2024 [24] - The company raised $3,900,000 in debt financing during the quarter, primarily from existing investors [24] Q&A Session Summary Question: Can you provide details on the Phase two portion of the CDMO contract? - The transition to Phase two involves moving from solid media to liquid media for cell conditioning, expected to take six to nine months [28][30] Question: How long will it take to narrow down targets with Tate and Lyle? - Significant work is underway, with a comprehensive update expected before the end of the year [32] Question: Should we anticipate continued gross margin expansion? - Management expects continued improvements in gross margins alongside revenue growth [34] Question: How many products contributed to revenue in Q1? - The majority of revenue came from three product lines, with expectations to increase to four by Q2 [39][40] Question: Will marketing costs drop due to increased ad inventory? - The company is focused on reducing marketing costs as a percentage of revenue while exploring new channels [42][46] Question: Does the second quarter guidance include CDMO contributions? - Yes, it includes revenue recognition from existing projects and potential new catalysts [47] Question: How many CDMO programs can be run concurrently? - The company can handle five to seven projects at one time in the initial stages [51] Question: What is the timeline for the olive cell product? - The product is expected to launch in 2026, with a faster ramp-up anticipated due to complementary marketing strategies [84]

Financial Performance - Revenues for the three-month period ended March 31, 2025, increased to $7,860,000, a 47% increase from $5,344,000 in the same period of 2024[6] - Gross profit for the same period was $4,595,000, compared to $3,003,000 in 2024, reflecting a gross margin improvement[6] - Operating loss for Q1 2025 was $1,719,000, slightly higher than the loss of $1,424,000 in Q1 2024[6] - Net loss for the three months ended March 31, 2025, was $2,338,000, a significant reduction from $6,581,000 in the prior year[6] - The Products business unit generated revenues of $7,690, while the CDMO Services unit contributed $170[58] - The net loss for the three months ended March 31, 2025, was $2,338, compared to a net loss of $6,581 in the same period of 2024, indicating a significant reduction in losses[58][60] Assets and Liabilities - Total current assets increased to $9,643,000 as of March 31, 2025, up from $7,856,000 in 2024, driven by higher cash and inventory levels[4] - Total liabilities rose to $27,467,000, compared to $23,671,000 in 2024, primarily due to an increase in loans from $3,905,000 to $7,497,000[4] - The accumulated deficit as of March 31, 2025, was $98,756,000, up from $96,418,000 in 2024, indicating ongoing financial challenges[4] - Cash and cash equivalents at the end of Q1 2025 were $3,401,000, a slight decrease from $3,436,000 at the end of Q1 2024[11] Financing and Funding - The company plans to fund its near-term activities through capital fundraising and debt instruments, highlighting reliance on external financing[20] - The company has not yet commenced generating sufficient sales to fund its operations, raising concerns about its ability to continue as a going concern[20] - The Company received $1,797 from new loan facilities during the three-month period ended March 31, 2025, with interest rates of 5%, 10%, and 12% per annum[48] - The Company has not yet closed the convertible loan facilities as of March 31, 2025, with a total balance of $483 from new loan facilities[48] - Following March 31, 2025, the Company received an additional $2,051 from 12% interest rate loan facilities[64] - The Company plans to extend the Early Conversion Warrants and Major Investor Warrants held by lenders for an additional 24 months as part of the new loan facilities[48] Shareholder Information - The company has a total of 17,327,716 common shares issued and outstanding as of March 31, 2025[32] - The company has 1,891,114 options outstanding with a weighted average exercise price of $6.30 as of March 31, 2025[36] - The company has 73,557 warrants outstanding with an average exercise price of $7.58 as of March 31, 2025[40] Management and Compensation - The Company’s key management personnel compensation increased, with the CEO's management fees rising to $191 from $117 year-over-year[50] - The company recognized equity settled compensation of $132,000 for the three months ended March 31, 2025, compared to $133,000 for the same period in 2024[35] Operational Insights - The company has two operating segments: Products and CDMO Services, with management evaluating performance based on operating profit[54][58] - No single customer accounted for 10% or more of total revenue for the three months ended March 31, 2025[62] - The average monthly lease fee for the Yavne manufacturing facility is NIS 101 ($28), subject to annual increases[29] - The company believes it is probable that the two extension options for the Yavne manufacturing facility lease will be exercised, extending the lease until September 2026[30] - The company did not issue any new options during the three months ended March 31, 2025, but had 214,885 options granted in the previous period[36] - The company has not closed any loan facilities as of March 31, 2025[45]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights into sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance its content creation and workflow processes [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

BioHarvest Sciences Reports First Quarter 2025 Financial ResultsFirst Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management GuidanceMay 15, 2025 4:05 PM EDT | Source: BioHarvest Sciences Inc.Rehovot, Israel--(Newsfile Corp. - May 15, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the first quarter ended March ...

The market expects BioHarvest Sciences Inc. (BHST) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to ...

Unaudited Interim Condensed Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2024 Expressed in U.S. dollars in thousands BioHarvest Sciences Inc. BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2024 Expressed in U.S. dollars in thousands TABLE OF CONTENTS | | Page | | --- | --- | | FINANCIAL STATEMENTS: | | | Unaudited Interim Condensed Consolidated Statements of Financial Position | 3 ...

BioHarvest Sciences Inc. 2 BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three and Six Months Ended June 30, 2024 Expressed in U.S. dollars in thousands BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three and Six Months Ended June 30, 2024 Expressed in U.S. dollars in thousands TABLE OF CONTENTS | | Page | | --- | --- | | FINANCIAL STATEMENTS: | | | Unaudited Interim Condensed Consolidated Statements of Financi ...